Search

everythinglearnresearchcommunity

for

Search:↓

User TH1RT33N_DR34M shares that MinoxidilMax plans to make topical Procyanidin B2 within a month. Users discuss the legitimacy of the product, quality control, and potential results from using it for hair loss.

The user is frustrated about not hearing any updates on the HMI-115 trial for hair loss. They are questioning if there will be any updates in the future.

The conversation discusses arranging an interview with the developers of RU58841 to clarify its safety and reasons for halted research, with some users expressing concerns about potential risks and others citing financial reasons for the discontinuation of studies. Specific treatments mentioned include RU58841, minoxidil, and finasteride.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

Minoxidil and finasteride are discussed for hair loss, with concerns about minoxidil's heart-related side effects. New treatments like PP405 are met with skepticism, often humorously noted as always being "five years away."

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

Users discuss using pyrilutamide for hair loss, seeking alternatives to 5AR inhibitors. They mention using minoxidil, ketoconazole shampoo, and RU58841.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

A trans woman is curious about the impact of HRT on hair regrowth and scalp tension. Her current regimen includes finasteride, spironolactone, estradiol, ketoconazole, vitamin D, iron, and plans to add oral minoxidil and restart derma rolling.

The user is using oral Minoxidil 2.5 mg, oral Finasteride 1 mg, and a 2mm derma roller for hair loss but feels discouraged by the lack of results after a month. They are seeking advice and considering additional methods like antiandrogens, exercise, and dietary changes.

The user started using 1mg finasteride and Regaine foam post-hair transplant, noticing significant hair growth at three months. They experienced testicular cramps as a side effect but no other issues, and are considering microneedling for further improvement.

A satirical take on the effects of using Verteporfin as a treatment for hair loss, with people pointing out that it is not accurate and has exaggerated outcomes. It was suggested that instead Minoxidil, Finasteride, or RU58841 should be used to treat hair loss.

New hair loss treatments PP405 and VDPHL01 are discussed with skepticism and hope, alongside existing treatments like minoxidil and finasteride. Users express frustration over limited progress since the 1980s but remain cautiously optimistic.

The conversation discusses whether not masturbating (semen retention) affects hair loss, with opinions varying but generally dismissing the idea. Some participants mention using hair loss treatments like Minoxidil, Finasteride, and RU58841, but the effectiveness and relation to prolactin levels in the scalp are debated.

PRP treatments for hair density show mixed results, with some users seeing minor improvements but not significant regrowth or halting of hair loss. Combining PRP with treatments like minoxidil, finasteride, or dutasteride may enhance results, but it is not a miracle solution.

The conversation is about using micro needling and PTD-DBM for hair loss treatment. The user applies PTD-DBM drops on weekdays and performs micro needling weekly.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

The user started using finasteride, minoxidil, and biotin for hair loss and believes they are a hyper responder, noticing significant changes in hair thickness. They regret not starting earlier and mention using oral minoxidil.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

The conversation discusses the differences between PG/Ethanol and KB solutions for RU58841 application, focusing on potential scalp irritation. KB solution is suggested for those allergic to PG, though both contain ethanol which can dry the scalp.

Minoxidil increases hair count despite high prolactin being linked to hair loss. Blocking DHT is effective, but not always necessary; HMI-115 is a promising treatment for androgenetic alopecia.

People are discussing the use of an untested hair loss treatment called PP405, which is not available on the grey market. Some users are trying a mimic formulation called HP3, reporting thicker hair but no new growth yet.

A fake hair loss product called "PP405" is being humorously discussed, with users joking about its effectiveness and availability on resale websites. The consensus is that it's a scam, with some users sarcastically claiming miraculous results.

The conversation discusses using finasteride, dutasteride, RU58841, and testosterone to combat hair loss and block DHT, with some users expressing concerns about side effects and vegan options for medication. The discussion also touches on personal experiences with hormone treatments and the desire to maintain a youthful appearance.

PP405 is a potential hair loss treatment that may activate dormant hair follicles, but there are concerns about its effectiveness, cost, and side effects. Users discuss treatments like minoxidil, finasteride, and RU58841, expressing skepticism about PP405's long-term success and accessibility.

PP405 shows promise for hair growth with significant results after 4 weeks, but skepticism exists due to its unavailability. Some users are hopeful for its potential, while others express concerns about side effects and market release delays.